drugset
drugset / Trial / NCT05701709

Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

NCT05701709 ↗

Phase 1 Recruiting 395 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study was designed to evaluate the efficacy, safety, and pharmacokinetics of SHR2102 in patients with advanced solid tumors. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of SHR-A2102 in phase II study.

Timeline

Start
2023-04-06
Primary completion
2025-08-31
Completion
2025-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-A2102 Other / unclassified — Intravenous

Indications

cancer